Low-Dose Paroxetine (7.5 MG) Improves Sleep in Women With Vasomotor Symptoms Associated With Menopause
Sleep disturbances are common among women in midlife; prevalence increases among perimenopausal/ postmenopausal women with vasomotor symptoms. Paroxetine 7.5 mg is the only nonhormonal treatment that has been approved in the United States for moderate to severe vasomotor symptoms associated with menopause. In two pivotal phase 3 studies evaluating its efficacy and safety, improvements in sleep disturbances were also prospectively evaluated.
Book a meeting or send us a message to talk to one of our experts.